Kanker-actueel = Zometa zoledronic acid (a bisphosphonate) Information: Zometa provides significantly better results in randomized phase III study in patients with recurrent prostate cancer and as an addition to hormone treatments.

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

= Zometa zoledronic acid immediately after surgery in women with early breast cancer who Femara - Letrozole use provides better protection against bone loss and disease-free time than when Zometa is given only after significant bone loss or fracture occurs. Thus 3-year evaluation of Phase III trial of Z-FAST 602 breast cancer patients. Article updated October 1, 2009.

= Zometa zoledronic acid (a bisphosphonate) receives FDA approval for drug use in bone problems of cancer, including prostate cancer and multiple myeloma patients - Multiple Myeloma patients. Article posted February 2002

= Zometa zoledronic acid provides significantly less risk of breaking bones and better recovery (81%) of bone problems and provides significantly better overall survival in breast, prostate and lung cancer patients compared with botuitzaaiingen APD and placebo, according to three large Phase III trials. Article updated October 1, 2009

= Zometa zoledronic acid (a bisphosphonate) gives 4 mg dose. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler) Scroll for study reports, etc. Article Update February 22, 2010

= Zometa zoledronic acid (a bisphosphonate) Information: New study shows once again increase our value and effectiveness of Zometa = zoledronic acid compared with APD injections for bone problems of cancer patients

= Zometa zoledronic acid (a bisphosphonate) Information: Zometa provides significantly better results in randomized phase III study in patients with recurrent prostate cancer and as an addition to hormone treatments.

= Zometa zoledronic acid (a bisphosphonate) Information: FDA warns against excessive dose of Zometa for patients with kidney problems. This may not exceed 4 mg. by injection administered.

= Zometa zoledronic acid (a bisphosphonate) information: A survey of three double-blind randomized controlled trials shows that Zometa - zoledronic ACD far better results than APD = pamidronate on bone problems (eg fractures), longer time to first occur and significantly reduces botuitzaaiingen The bone pain in breast cancer, but also in bone metastatic prostate cancer, lung cancer, renal cell cancer and other solid tumors. Article posted October 24, 2005

= Zometa zoledronic acid (a bisphosphonate) shows work best and even cost-effective means to botversterkende against bone loss in solid tumors. Article posted June 30, 2008

= Zometa zoledronic acid (a bisphosphonate) prevents bone loss in women with early breast cancer undergoing chemotherapy, according to randomized placebo-controlled phase III study. Article posted August 23, 2008

Zoledronic acid 4 mg dose gives. given intravenously in randomized phase III trial (1600 patients over 25 months) significantly more effect on bone problems than APD - 90 mg pamidronate. in breast cancer patients and patients with MM - Multiple Myeloma (Kahler)

Zoledronic acid - Zometa significantly prolongs life in patients with multiple myeloma (Multiple Myeloma).

Bisphosphonates often cause bone problems in the jaw - osteonecrosis - evidenced by two recent studies. Article posted February 25, 2011

Zometa - zoledronic acid significantly prevents recurrence in women with breast cancer after the menopause and gives significantly better results in survival, but not in younger women. Estrogen levels appears to play a decisive role. Thus, large phase III study. Article updated March 19, 2011

Bisphosphonates increase in femur fracture risk but this risk does not outweigh benefits of bisphosphonates, according to major Swedish research in breast cancer patients. Article posted May 5, 2011

Learn how Zometa - zoledronic acid can be prescribed and fully compensated and given home can get. Article updated June 8, 2011

Zometa - zoledronic acid in addition to tamoxifen or Armidex disease-free time and better overall survival in breast cancer patients with hormone sensitive breast cancer, shows large randomized phase III study. Article posted June 8, 2011

Zometa - zoledronic acid for breast cancer in algmeen shows no significant positive effect only for postmenopausal women with breast cancer, Zometa in addition to chemotherapy 25 percent longer disease-free and overall survival it. A very special result. Article posted September 27, 2011

= Zometa zoledronic acid (a bisphosphonate) Information: Zometa provides significantly better results in randomized phase III study in patients with recurrent prostate cancer and as an addition to hormone treatments.

March 22, 2005: Source: J Natl Cancer Inst. Oct 2 2002, 94 (19) :1458-68.

Earlier we had published this study but can not easily find on the site and also belongs to all information on Zometa - zoledronic acid to stand. So here again, and references to the abstract discussion in major medical journals on Zometa and effect in prostate cancer patients.

Comment in:
BJU Int. April 2003, 91 (6) :464-5.
J Natl Cancer Inst. Oct 2 2002, 94 (19) :1422-3.
J Natl Cancer Inst. 6 August 2003, 95 (15) :1174-5, author reply 1175.
J Natl Cancer Inst. 2003 in February 1919, 95 (4) :332-3, author reply 333-4.
J Natl Cancer Inst. 2003 in February 1919, 95 (4): 332, author reply 333-4.
J Natl Cancer Inst. 2003 in February 1919, 95 (4): 332, author reply 333-4.
J Natl Cancer Inst. 2004 August 4, 1996 (1915): 1183, author reply 1183-1184.
J Natl Cancer Inst. 2004 Oct 6, 1996 (1919): 1480, author reply 1480-1.
J Natl Cancer Inst. 2 February 2005, 97 (3) :235-6.

A randomized, placebo-controlled trial of zoledronic acid in patient with hormone-refractory prostate carcinoma meta-static.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ Goas JA, Chen B, zoledronic Acid Prostate Cancer Study Group. Uro-Oncology Clinic, Centre Hospitalier de l'Université de Montréal, Hopital Notre-Dame, Montreal, Quebec, Canada. fred.saad @ ssss.gouv.qc.ca

BACKGROUND: Bone metastases are a common cause of morbidity in patient with prostate carcinoma. We studied the effect of a new bisphosphonates, zoledronic acid, Which blocks bone destruction, on Skeletal Complications in prostate cancer patients with bone metastases. METHODS: Patients with hormone-refractory prostate cancer and a history of bone metastases Were Randomly Assigned to a double-blind treatment regimen of intravenous zoledronic acid at 4 mg (N = 214), zoledronic acid at 8 mg (subsequently Reduced to 4 mg; 8 / 4) (N = 221), or placebo (N = 208) every 3 weeks for 15 months. Proportions of Patients with skeletal-related events, the time to first skeletal-related event, skeletal morbidity rate, pain and Analgesic scores, disease progression, and safety Were assessed. All statistical tests Were two-sided.

RESULTS: Approximately 38% of Patients who Received at zoledronic acid 4 mg, 28% who Received zoledronic acid at 8 / 4 mg, and 31% Received placebo who completed the study. A Greater Proportion of Patients who Received placebo had skeletal-related events Than Those Who Received at 4 mg zoledronic acid (44.2% versus 33.2%, difference = -11.0%, 95% confidence interval = 2,079,702,307 -20.3% to -1.8%, P =. 021) or zoledronic acid at Those Who Received 8 / 4 mg (38.5% difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%, P =. 222). Median time to first skeletal-related event was 321 days for Patient who Received placebo was not Reached for Patient who Received at zoledronic acid 4 mg (P =. 011 vs placebo), and was 363 days for Those Who Received zoledronic acid at 8 / 4 mg (P =. 491 vs. placebo). Compared with urinary markers in Patients who Received placebo, urinary markers of bone resorption statistically significantly Were Decreased in Patients who Received Either at zoledronic acid dose (P =. 001). Pain and Analgesic Scores Increased in Patients who Received placebo more Than in Patients who Received zoledronic acid, but Were there no differences in disease progression, performance status, or quality-of-life scores among the groups. Zoledronic acid at 4 mg Given as a 15-minute infusion was well tolerated, but the 8-mg dose was associated with renal function Deterioration.

CONCLUSION: zoledronic acid at 4 mg Reduced skeletal-related events in prostate cancer patients with bone metastases. PMID: 12359855 [PubMed - indexed for MEDLINE]